Fibrosis disease can manifest in many areas of the body, the result of a deregulated wound healing process after injury, which can lead to high mortality. With two drugs recently reaching marketed status for IPF (Idiopathic Pulmonary Fibrosis), there is continued growth and investment to identify new treatments, including for other conditions such as liver fibrosis and diabetic nephropathy. Fibrosis has complex disease pathology and greater knowledge of mechanisms is sought. This symposium will cover drug discovery and medicinal chemistry aspects of fibrotic conditions from leading experts in the field.
The conference will be of interest to researchers, academics, students and industrialists with an interest in fibrosis disease, medicinal chemistry and drug discovery.
Programme
-An overview of liver and kidney fibrosis
Dr Fiona Oakley, University of Newcastle, UK
-Idiopathic pulmonary fibrosis: Impact of current treatments, limitations and opportunities
Dr Hannah Woodcock, University College London, UK
-αv integrin modulators for fibrosis and the profile of an αvβ6 clinical candidate
Dr Simon Macdonald, GlaxoSmithKline, UK
-Discovery and development of galectin-3 ligand mimetics as anti-fibrosis compounds
Prof Ulf Nilsson, Lund University, Sweden
-Discovery of GLPG1690: a first-in-class autotoxin inhibitor in clinical development for the treatment of idiopathic pulmonary fibrosis
Dr Nicolas Desroy, Galapagos, France
-Porcupine inhibitors as anti-fibrotic therapies
Dr Cliff Jones, Redx Pharma Plc, UK
-Cannabinoid Receptor (CB1R) based dual-target approaches for the treatment of fibrotic conditions
Dr Malliga Iyer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA
Early bird fees before Friday 29 September 2017
Standard fees after Friday 29 September 2017
The conference will be of interest to researchers, academics, students and industrialists with an interest in fibrosis disease, medicinal chemistry and drug discovery.
Programme
-An overview of liver and kidney fibrosis
Dr Fiona Oakley, University of Newcastle, UK
-Idiopathic pulmonary fibrosis: Impact of current treatments, limitations and opportunities
Dr Hannah Woodcock, University College London, UK
-αv integrin modulators for fibrosis and the profile of an αvβ6 clinical candidate
Dr Simon Macdonald, GlaxoSmithKline, UK
-Discovery and development of galectin-3 ligand mimetics as anti-fibrosis compounds
Prof Ulf Nilsson, Lund University, Sweden
-Discovery of GLPG1690: a first-in-class autotoxin inhibitor in clinical development for the treatment of idiopathic pulmonary fibrosis
Dr Nicolas Desroy, Galapagos, France
-Porcupine inhibitors as anti-fibrotic therapies
Dr Cliff Jones, Redx Pharma Plc, UK
-Cannabinoid Receptor (CB1R) based dual-target approaches for the treatment of fibrotic conditions
Dr Malliga Iyer, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, USA
Early bird fees before Friday 29 September 2017
- GB£80 . . . . . . . . . . . . . . . . . SCI/RSC Member
- GB£35 . . . . . . . . . . . . . . . . . SCI/RSC Student Member
- GB£50 . . . . . . . . . . . . . . . . . SCI/RSC Subsidised Member
- GB£120 . . . . . . . . . . . . . . . ..Non-Member
Standard fees after Friday 29 September 2017
- GB£110 . . . . . . . . . . . . . . . . . SCI/RSC Member
- GB£50 . . . . . . . . . . . . . . . . . . SCI/RSC Student Member
- GB£75 . . . . . . . . . . . . . . . . . . SCI/RSC Subsidised Member
- GB£150 . . . . . . . . . . . . . . . . . Non-Member
